Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Allogene Therapeutics, Inc. Transaction History
Mitsubishi Ufj Kokusai Asset Management Co., Ltd.
- $122 Billion
- Q2 2025
A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 138,900 shares of ALLO stock, worth $179,181. This represents 0.0% of its overall portfolio holdings.
Number of Shares
138,900
Previous 264,065
47.4%
Holding current value
$179,181
Previous $385,000
59.48%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding ALLO
# of Institutions
169Shares Held
162MCall Options Held
146KPut Options Held
97.1K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$24.1 Million1.28% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$21.2 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA11.2MShares$14.4 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR11.1MShares$14.3 Million3.7% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.5MShares$13.5 Million0.5% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $186M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...